Literature DB >> 14569385

[Sacral neuromodulation in treatment of functional disorders of the lower urinary tract. An overview of basic principles, indications, outcomes].

A Bannowsky1, C Seif, S Sugimoto, G Böhler, C van der Horst, S Bross, P Alken, K-P Jünemann, P M Braun.   

Abstract

Over the last few years, sacral neuromodulation has become an established treatment option for dysfunctions of the lower urinary tract. It fills the gap that used to exist between conservative therapy and costly invasive methods such as urinary drainage via a deactivated bowel segment. Initially, the clinical value of sacral neuromodulation was controversial even among neurourologists. This was mainly due to a lack of understanding of the physiological processes, uncertain diagnostics, the design of the hardware, and a surgical topography relatively unknown to the urologist. In the meantime, however, sacral neuromodulation has become a standard part of clinical routine with respect to the treatment of dysfunctions of the lower urinary tract, and it is regularly employed in various urological institutions across Europe and the USA. This form of treatment, which is the final straw for patients who believed themselves-after many frustrated therapy attempts-to be "hopeless cases," can now also successfully be employed as an ambulatory measure. The latest data from our hospital, as well as contributions presented at the last DGU Congress in Wiesbaden, indicate that patients with neurogenic urinary retention are the most likely to profit from this treatment option.

Entities:  

Mesh:

Year:  2003        PMID: 14569385     DOI: 10.1007/s00120-003-0343-2

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  37 in total

1.  Effect on urinary bladder of unilateral stimulation of pelvic nerves in the dog.

Authors:  E H INGERSOLL; L L JONES; E S HEGRE
Journal:  Am J Physiol       Date:  1957-04

2.  The innervation of the bladder and urethra.

Authors:  T R Elliott
Journal:  J Physiol       Date:  1907-07-02       Impact factor: 5.182

3.  Management of voiding dysfunction with an implantable neuroprosthesis.

Authors:  S W Siegel
Journal:  Urol Clin North Am       Date:  1992-02       Impact factor: 2.241

4.  Reflex activation of sympathetic pathways to vesical smooth muscle and parasympathetic ganglia by electrical stimulation of vesical afferents.

Authors:  W C de Groat; R J Theobald
Journal:  J Physiol       Date:  1976-07       Impact factor: 5.182

5.  Functional evaluation of sacral nerve root integrity. Report of a technique.

Authors:  R A Schmidt; E Senn; E A Tanagho
Journal:  Urology       Date:  1990-05       Impact factor: 2.649

6.  Innervation of the vesical detrusor muscle by the ganglia of the pelvic plexus.

Authors:  W E Bradley; C T Teague
Journal:  Invest Urol       Date:  1968-11

7.  The effect of pelvic nerve stimulation on detrusor contraction.

Authors:  A C Diokno; R Davis; J Lapides
Journal:  Invest Urol       Date:  1973-11

8.  Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence.

Authors:  K E Matzel; U Stadelmaier; M Hohenfellner; F P Gall
Journal:  Lancet       Date:  1995-10-28       Impact factor: 79.321

9.  Neuromodulation of sacral nerves for incontinence and voiding dysfunctions. Clinical results and complications.

Authors:  H E Dijkema; E H Weil; P T Mijs; R A Janknegt
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

10.  Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence.

Authors:  R A Janknegt; M M Hassouna; S W Siegel; R A Schmidt; J B Gajewski; D A Rivas; M M Elhilali; D C Milam; P E van Kerrebroeck; H E Dijkema; A A Lycklama à Nÿeholt; M Fall; U Jonas; F Catanzaro; C J Fowler; K A Oleson
Journal:  Eur Urol       Date:  2001-01       Impact factor: 20.096

View more
  1 in total

1.  Urodynamic changes and response rates in patients treated with permanent electrodes compared to conventional wire electrodes in the peripheral nerve evaluation test.

Authors:  Andreas Bannowsky; Björn Wefer; Peter Martin Braun; Klaus-Peter Jünemann
Journal:  World J Urol       Date:  2008-07-16       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.